Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 179

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia

Open access
Currow, D., Temel, J.S., Abernethy, A., Milanowski, J., Friend, J., Fearon, K.C.·2017·Annals of Oncology

Abstract

BACKGROUND: Cancer anorexia-cachexia is a debilitating condition frequently observed in NSCLC patients, characterized by decreased body weight, reduced food intake, and impaired quality of life. Anamorelin, a novel selective ghrelin receptor agonist, has anabolic and appetite-enhancing activities. PATIENTS AND METHODS: ROMANA 3 was a safety extension study of two phase 3, double-blind studies that assessed safety and efficacy of anamorelin in advanced NSCLC patients with cachexia. Patients with preserved Eastern Cooperative Oncology Group ≤2 after completing 12 weeks (w) on the ROMANA 1 or ROMANA 2 trials (0-12 weeks) could enroll in ROMANA 3 and continue to receive anamorelin 100 mg or placebo once daily for an additional 12w (12-24 weeks). The primary endpoint of ROMANA 3 was anamorelin safety/tolerability (12-24 weeks). Secondary endpoints included changes in body weight, handgrip strength (HGS), and symptom burden (0-24 weeks). RESULTS: Of the 703 patients who completed ROMANA 1 and ROMANA 2, 513 patients entered ROMANA 3 (anamorelin, N = 345, mean age 62.0 years; placebo, N = 168; mean age 62.2 years). During ROMANA 3, anamorelin and placebo groups had similar incidences of treatment-emergent adverse events (TEAEs; 52.2% versus 55.7%), grade ≥3 TEAEs (22.4% versus 21.6%), and serious TEAEs (12.8% versus 12.6%). There were 36 (10.5%) and 23 (13.8%) deaths in the anamorelin and placebo groups, respectively; none were drug-related. Improvements in body weight and anorexia-cachexia symptoms observed in the original trials were consistently maintained over 12-24 weeks. Anamorelin, versus placebo, significantly increased body weight from baseline of original trials at all time points (P < 0.0001) and improved anorexia-cachexia symptoms at weeks 3, 6, 9, 12, and 16 (P < 0.05). No significant improvement in HGS was seen in either group. CONCLUSION: During the 12-24 weeks ROMANA 3 trial, anamorelin continued to be well tolerated. Over the entire 0-24w treatment period, body weight and symptom burden were improved with anamorelin. CLINICAL TRIAL REGISTRATION NUMBERS: ROMANA 1 (NCT01387269), ROMANA 2 (NCT01387282), and ROMANA 3 (NCT01395914).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdx192

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 25

  1. Fearon, 2011, Definition and classification of cancer cachexia: an international consensus, Lancet Oncol, 12, 489, 10.1016/S1470-2045(10)70218-7 · DOI · Paper page
  2. Von Haeling, 2014, Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014, J Cachexia Sarcopenia Muscle, 5, 261, 10.1007/s13539-014-0164-8 · DOI · Paper page
  3. Fearon, 2013, Understanding the mechanisms and treatment options in cancer cachexia, Nat Rev Clin Oncol, 10, 90, 10.1038/nrclinonc.2012.209 · DOI · Paper page
  4. Kimura, 2015, Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer, Support Care Cancer, 23, 1699, 10.1007/s00520-014-2534-3 · DOI · Paper page
  5. Granda-Cameron, 2010, An interdisciplinary approach to manage cancer cachexia, Clin J Oncol Nurs, 14, 72, 10.1188/10.CJON.72-80 · DOI
  6. Davis, 2012, The emerging role of palliative medicine in the treatment of lung cancer patients, Cleve Clin J Med, 79, eS51, 10.3949/ccjm.79.s2.11 · doi:10.3949/ccjm.79.s2.11
  7. Wallengren, 2013, Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity and survival in unselected palliative care patients, Support Care Cancer, 21, 1569, 10.1007/s00520-012-1697-z · DOI · Paper page
  8. Guillory, 2013, The role of ghrelin in anorexia-cachexia syndromes, Vitam Horm, 92, 61, 10.1016/B978-0-12-410473-0.00003-9 · DOI
  9. Lundholm, 2010, Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study, Cancer, 116, 2044, 10.1002/cncr.24917 · DOI
  10. Hiura, 2012, Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: a prospective, randomized, placebo-controlled phase 2 study, Cancer, 118, 4785, 10.1002/cncr.27430 · DOI
  11. Strasser, 2008, Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study, Br J Cancer, 98, 300, 10.1038/sj.bjc.6604148 · DOI · Paper page
  12. Currow, 2014, Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome, Future Oncol, 10, 789, 10.2217/fon.14.14 · DOI
  13. Garcia, 2013, Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study, Support Care Cancer, 21, 129, 10.1007/s00520-012-1500-1 · DOI · Paper page
  14. Temel, 2013, Efficacy and safety of anamorelin HCl in NSCLC patients: results from a randomized, double-blind, placebo-controlled, multicentre phase II study, Eur J Cancer, 49, S269
  15. Ribaudo, 2000, Re-validation and shortening of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire, Qual Life Res, 9, 1137, 10.1023/A:1016670403148 · DOI · Paper page
  16. Heppner, 2014, Mechanisms in endocrinology: regulation of glucose metabolism by the ghrelin system: multiple players and multiple actions, Eur J Endocrinol, 171, R21, 10.1530/EJE-14-0183 · DOI
  17. Honors, 2012, The role of insulin resistance in the development of muscle wasting during cancer cachexia, J Cachexia Sarcopenia Muscle, 3, 5, 10.1007/s13539-011-0051-5 · DOI · Paper page
  18. Murphy, 1998, MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism, J Clin Endocrinol Metab, 83, 320
  19. Vestergaard, 2008, Acute effects of ghrelin administration on glucose and lipid metabolism, J Clin Endocrinol Metab, 93, 438, 10.1210/jc.2007-2018 · DOI
  20. Leese, 2015, An open-label clinical trial of the effects of age and gender on the pharmacodynamics, pharmacokinetics and safety of the ghrelin receptor agonist anamorelin, Clin Pharmacol Drug Dev, 4, 112, 10.1002/cpdd.175 · DOI
  21. Tuca, 2013, Clinical evaluation and optimal management of cancer cachexia, Crit Rev Oncol Hematol, 88, 625, 10.1016/j.critrevonc.2013.07.015 · DOI
  22. Fearon, 2008, Cancer cachexia: developing multimodal therapy for a multidimensional problem, Eur J Cancer, 44, 1124, 10.1016/j.ejca.2008.02.033 · DOI · Paper page
  23. Rhondali, 2013, Association between body image dissatisfaction and weight loss among patients with advanced cancer and their caregivers: a preliminary report, J Pain Symptom Manage, 45, 1039, 10.1016/j.jpainsymman.2012.06.013 · DOI
  24. Makrantonakis, 2004, Non-small cell lung cancer in the elderly, Oncologist, 9, 556, 10.1634/theoncologist.9-5-556 · doi:10.1634/theoncologist.9-5-556
  25. Maione, 2010, Treating advanced non-small cell lung cancer in the elderly, Ther Adv Med Oncol, 2, 251, 10.1177/1758834010366707 · DOI

Cited by

See all 179

Metadata

Authors
Currow, D., Temel, J. S., Abernethy, A., Milanowski, J., Friend, J., & Fearon, K. C.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2017-08
Volume
28
Issue
8
Pages
1949-1956
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2611376562
Cited by
179
References
2
FWCI
11.33
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia. https://app.cochat.ai/papers/10.1093/annonc/mdx192
The paper
Currow, D., Temel, J. S., Abernethy, A., Milanowski, J., Friend, J., & Fearon, K. C. (2017). ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia. Annals of Oncology. https://doi.org/10.1093/annonc/mdx192

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.